{"nctId":"NCT00993473","briefTitle":"6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","startDateStruct":{"date":"2009-10"},"conditions":["Type 1 Diabetes Mellitus"],"count":125,"armGroups":[{"label":"Lantus (insulin glargine)","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin glargine (HOE901)","Drug: Insulin lispro"]},{"label":"NPH insulin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Neutral Protamine Hagedorn (NPH) insulin","Drug: Insulin lispro"]}],"interventions":[{"name":"Insulin glargine (HOE901)","otherNames":["Lantus®"]},{"name":"Neutral Protamine Hagedorn (NPH) insulin","otherNames":[]},{"name":"Insulin lispro","otherNames":["Humalog®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Pediatric patients with type 1 diabetes mellitus aged at least one year to less than 6 years at screening, for whom signed written informed consent has been obtained from parent or legal guardian to participate in the study\n\nExclusion criteria:\n\n* Diagnosis of type 1 diabetes for less than one year\n* HbA1c at screening \\>12% or \\<6%\n* Diabetes other than type 1 diabetes\n* Parents and patients not willing to undergo all study assessments and treatments, including home blood glucose monitoring, Continuous Glucose Monitoring System (CGMS) sensor placement and maintenance both at the site and at home, multiple daily insulin injections, and visits, as dictated by the protocol (if a telephone is not available patients may undergo all visits in person)\n* Patients and families for whom 6 days in total (not necessarily continuous) of useable CGMS data cannot be obtained (either by home sensor replacement, or by sensor replacement at the site at additional screening visits if needed) during the screening CGMS evaluations between Visit 2 and the randomization visit\n* Patients treated with insulin pump therapy during the two months prior to screening\n* History of primary seizure disorder\n* History of severe hypoglycemic episode accompanied by seizure and/or coma, or diabetic ketoacidosis leading to hospitalization or to care in the emergency ward, in the 2 months prior to the screening visit\n* Need for chronic treatment with acetaminophen (paracetamol)-containing medications\n* Serum creatinine \\> 2.0mg/dL at screening\n* Serum ALT or AST greater than 3x upper limit of normal for the patient's age and gender, at screening\n* Hemoglobin \\< 10g/dL, or platelet count less than 100,000/cu mm, at screening\n* Treatment with any pharmacologic anti-hyperglycemic oral agent for more than 3 months at any time\n* Treatment with any non-insulin antihyperglycemic medication (eg, Symlin®) for the 3 months prior to screening\n* Treatment with systemic glucocorticoids within the month prior to screening\n\nAbove information not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event Rate of \"All Hypoglycemia\" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)","description":"The rate of \"all hypoglycemia\" was calculated from \"all hypoglycemia\" episodes which occurred during the 24-week on-treatment period and consisted of: - symptomatic hypoglycemia episodes validated by the study investigator based on entries in patients' diaries, - low continuous glucose monitoring system (CGMS) excursions (interstitial glucose \\<70 mg/dL \\[3.9 mmol/L\\]) confirmed by fingerstick blood glucose (FSBG) \\<70 mg/dL, - low FSBG readings (values \\<70 mg/dL) performed at other times.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192.75","spread":"119.28"},{"groupId":"OG001","value":"168.91","spread":"101.04"}]}]}]},{"type":"SECONDARY","title":"Event Rate of Symptomatic Hypoglycemia (Individual Component of Primary Endpoint) Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)","description":"Symptomatic hypoglycemia: any event with clinical symptoms considered to result from hypoglycemia, validated by the study investigator based on data from patient diaries.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.54","spread":"37.25"},{"groupId":"OG001","value":"33.02","spread":"47.95"}]}]}]},{"type":"SECONDARY","title":"Event Rate of Severe Symptomatic Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years","description":"Severe symptomatic hypoglycemia: any event with clinical symptoms considered to result from a hypoglycemic episode for which the patients required the assistance of a third party (ie, other than the patient, or a parent/usual caregiver; eg, from emergency personnel), because the patients/parents could not treat the event with acute neurological impairment directly resulting from the hypoglycemic event. The occurrence of seizure, coma, unconsciousness, or the use of glucagon, were also to qualify a hypoglycemic episode as severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.55"},{"groupId":"OG001","value":"0.07","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Event Rate of Nocturnal Hypoglycemia Defined as the Total Number of \"All Hypoglycemia\" Episodes Divided by the Total Duration of the On-treatment Period in Years","description":"Nocturnal hypoglycemia: any event from the \"all hypoglycemia\" total that occurred between 23:00 and 07:00 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.50","spread":"25.62"},{"groupId":"OG001","value":"30.92","spread":"24.97"}]}]}]},{"type":"SECONDARY","title":"Event Rate of Nocturnal Symptomatic Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years","description":"Nocturnal symptomatic hypoglycemia: any symptomatic hypoglycemic event that occurred between 23:00 and 07:00 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"5.42"},{"groupId":"OG001","value":"3.65","spread":"6.75"}]}]}]},{"type":"SECONDARY","title":"Event Rate of Severe Nocturnal Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years","description":"Severe nocturnal symptomatic hypoglycemia: any severe symptomatic hypoglycemic event that occurred between 23:00 and 07:00 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.29"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Glycosylated Hemoglobin A1c (HbA1c): End of Treatment and Change From Baseline to End of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.023","spread":"1.049"},{"groupId":"OG001","value":"8.248","spread":"1.429"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.071","spread":"0.884"},{"groupId":"OG001","value":"8.344","spread":"1.161"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.036","spread":"0.979"},{"groupId":"OG001","value":"0.000","spread":"1.035"}]}]}]},{"type":"SECONDARY","title":"Glycosylated Hemoglobin A1c (HbA1c): End of Treatment and Change From Baseline to End of Treatment (ANCOVA Estimates)","description":"Assessed using an analysis of covariance (ANCOVA) model with treatment, and randomization strata (baseline number of CGM hypoglycemic excursions \\<0.5 events/24hours or ≥0.5 events/24 hours, and baseline HbA1c \\<8.5% or ≥8.5%) as fixed effects, and using the baseline value as covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.139","spread":"0.1065"},{"groupId":"OG001","value":"8.232","spread":"0.1134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.048","spread":"0.1065"},{"groupId":"OG001","value":"0.045","spread":"0.1134"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Reaching HbA1c Target of Less Than 7.5% at the End of Treatment Visit","description":"Percentage of patients reaching International Society for Pediatric and Adolescent Diabetes (ISPAD)-recommended goals of Glycosylated Hemoglobin A1c \\<7.5% at the end of treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"22.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Daily Blood Glucose (BG) Based on CGMS Values: End of Treatment and Change From Baseline to End of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.263","spread":"1.887"},{"groupId":"OG001","value":"11.170","spread":"1.986"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.085","spread":"2.077"},{"groupId":"OG001","value":"11.712","spread":"2.166"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.218","spread":"2.399"},{"groupId":"OG001","value":"0.501","spread":"1.906"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Different Types of Hypoglycemia Events","description":"Definitions of the different types of hypoglycemia events provided in the outcome measure description of the corresponding event rates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent of Blood Glucose (BG) Within the Range of 70 - 180 mg/dL (3.9-10 mmol/L)","description":"Calculated for each patient as the percent of all on-treatment CGMS values falling within the range of 70 - 180 mg/dL (3.9 - 10 mmol/L) inclusive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.667","spread":"12.048"},{"groupId":"OG001","value":"38.158","spread":"10.908"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blood Glucose Variability Based on All On-treatment CGMS Values","description":"Calculated for any given patient as the standard deviation (SD) of all CGMS interstitial glucose values recorded over all CGMS placements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.954","spread":"0.826"},{"groupId":"OG001","value":"5.089","spread":"0.731"}]}]}]},{"type":"POST_HOC","title":"Event Rate of \"All Confirmed Low CGMS Excursions\" (Individual Component of Primary Endpoint) Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)","description":"\"All confirmed low CGMS excursions\" consisted of all low continuous glucose monitoring system (CGMS) excursions (interstitial glucose \\<70 mg/dL \\[3.9 mmol/L\\]) confirmed by fingerstick blood glucose (FSBG) \\<70 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.61","spread":"74.09"},{"groupId":"OG001","value":"71.60","spread":"53.20"}]}]}]},{"type":"POST_HOC","title":"Event Rate of \"All Confirmed Low FSBG\" (Individual Component of the Primary Endpoint) Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)","description":"\"All confirmed low FSBG\" consisted of all low FSBG readings (values \\<70 mg/dL) performed at other times.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192.69","spread":"121.78"},{"groupId":"OG001","value":"168.24","spread":"101.21"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Nocturnal Blood Glucose Variability Based on All On-treatment CGMS Values","description":"Calculated for any given patient as the standard deviation (SD) of all CGMS interstitial glucose values recorded during the nocturnal time period (between 23:00 and 07:00 hours).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.747","spread":"0.973"},{"groupId":"OG001","value":"4.837","spread":"0.825"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":62},"commonTop":["Gastroenteritis","Nasopharyngitis","Upper respiratory tract infection","Pyrexia","Vomiting"]}}}